Jorge Conde
speaker
469 appearances
4 recordings
1 series
first heard Sep 2025
last heard 2 Sep
Jorge Conde’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Sep 2026 with 1.
Appearances
You're right.
A lot of biotech has been around like go after the low hanging fruit because it's low risk and we gotta eat today.
Right.
So you go get it, you know, and you decide to you push off the big the big ambitious indication, the large population or the the really uh tough to crack disease.
But I you know, I do think we're seeing more and more of that.
And by the way, like we can get into some of these genetic medicines, but some of these genetic medicines are going after some of the hardest problems, the things that you quite literally couldn't address but for editing, you know, DNA.
And you know, I think that's incredibly, you know, remarkable and laudable and and and cran frankly inspiring.
But the fundamental um elements of the industry have to work.
So the capital formation is there to support those kinds of things.
And right now it's hard.
Right, because of the the issues we talked about before.
Yeah, I look, I think um it's it's going to go back to uh sort of where we started uh this combination uh conversation, excuse me.
Uh GLP ones uh as a drug are, you know, what is it, four decades in the making or something like that.
You know, these are these are not overnight successes.
Um uh but I do think what we are going to see more of and and our hope is that when you combine the fact that we're getting better at uh understanding what to target.
Target.
getting better at designing medicines to hit those targets.
By the way, in a whole array of new creative ways.
So we have small molecules, the natural products that we got from boiling leaves, as you said earlier, like those have gotten, you know, we're getting really good at designing smarter and better smaller molecule small molecules that do new things, that function in ways that they didn't before.
Um, we've gotten quite good at designing uh uh biologics or proteins with a lot of help from things like Alpha Fold that help us understand how proteins fold.
Showing 401–420 of 469 · page 21 of 24
← Previous
Next →